Glenmark receives final approval from USFDA for generic Emend Capsules

16 Oct 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg, the generic version of Emend Capsules, 40 mg, 80 mg, and 125 mg, of Merck Sharp & Dohme Corporation.

According to IMS Health sales data for the 12 month period ending August 2017, the Emend Capsules, 40 mg, 80 mg, and 125 mg market achieved annual sales of approximately $64.9 million.

Glenmark’s current portfolio consists of 127 products authorized for distribution in the US marketplace and 60 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1990.65 -9.95 (-0.50%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×